Genomic Cancer Testing Market Synopsis:
Genomic Cancer Testing Market Size Was Valued at USD 16.67 Billion in 2023, and is Projected to Reach USD 48 Billion by 2032, Growing at a CAGR of 17% From 2024-2032.
The genomic cancer testing is one of the emerging stratified market segments within the sphere of oncology diagnostics as a result of the development of genetic technologies and the current tendency to shift from usual or conventional approaches to individualized medicine. Genomic cancer testing is, therefore, a diagnostic test that aims at determining the specific alteration of a gene of a specific cancer patient, their type of cancer and other parameters and possible response to treatment. Genomic testing in cancer therefore offers better understanding of the molecular nature, and leads to better targeted therapies that provide better patient outcomes with lesser toxicity.
Market growth is driven by the increasing incidence of the cancer, the advancements in NGS, and the advancement of genomics in cancer. Since NGS provides detailed genetic characterization of tumors for a reasonable price, genomic testing is gradually transitioning to critical applications in clinics. More so, the increasing popularity of precision medicine that focuses on delivering treatments based on one’s genes is playing a role in enhancing the size of the market. Blood-based cancer genomic tests are quickly gaining popularity and applied to various types of cancer, including breast, lung, colon, and prostate cancer, for early detection and accurate diagnosis and treatment.
Despite this, the market has its hurdles that include high costs of employing genomic testing, low insurance coverage, and a difficult interpretation of genetic tests. The other challenge is regulatory issues since the regulation when it comes to cancer historical analyze as well as genomic tests has been a challenge due to the need to ensure accuracy and verration within the test processes for acceptance of the medical practitioners and the state. However there are some challenges for the market, the key opportunities remain in the increasing investment in genomic research, advanced technologies and collaboration between pharma and diagnostics. With directed therapies being introduced and governmental approvals being made the genomic cancer testing will advance and are set to open up opportunities for early detection and treatment in cancer.
Genomic Cancer Testing Market Trend Analysis:
Increasing Adoption of Liquid Biopsy for Cancer Detection
- Another trend in the genomic cancer testing market that has been recognized is the constant shift from more invasive techniques to liquid biopsy. Liquid biopsy is the method of examining a patient’s blood or other fluids in the body searching for genetic alterations associated with cancer. This method is becoming popular because it can diagnose cancer at early stage, evaluate the growth of tumors and response to treatment, cross sectional studies with out invasive tissue biopsies. The factors that make liquid biopsy appealing include convenience, faster results, and lesser dangers that are progressive factors that contribute to the use of liquid biopsy emphasizing cancers such as lung, colorectal, and breast cancers.
Integration of Artificial Intelligence in Genomic Data Analysis
- Another important tendency is a use of artificial intelligence inclusive of machine learning in the genomic data analysis. Given the fact that genomic cancer testing produces a huge volume of somewhat structured data, there are efforts to apply AI solutions for better analysis of this data. These tools aid the clinicians in reading appropriate genetic mutations, capability to anticipate patient outcomes to particular medications, and useful in formulating individual outcomes. Machine learning abilities of AI in identifying patterns and providing high levels of prediction are enhancing the accuracy of genomic cancer tests, increasing the shelf space of precise diagnosis, and bolstering the advent of precision medicine in oncology.
Genomic Cancer Testing Market Segment Analysis:
Genomic Cancer Testing Market is Segmented on the basis of Test Type, Cancer Type, Technology, End-User, Biomarker Type, Service Provider, Application, Testing Setting, and Region
By Test Type, Genomic Profiling Tests segment is expected to dominate the market during the forecast period
- The genomic cancer testing market can be divided and categorized by type of test and each of these categories responds to various aspects of cancer. Genomic profiling are whole exome sequencing and targeted sequencing commonly used in identification of genetic anomalies of tumors, overall understanding of cancer mutation as well as developing individualized treatment plans. Blood-based diagnostic techniques are on the rise because of their minimally invasive approach; diagnosis of cancer at a preliminary stage and tracking of tumors through liquid biopsies. Companion diagnostic tests refer to useful tools of personalized medicine that help determine the particular form of therapy based on the molecular characteristics of the cancer in question, mainly in targeted therapies. Pharmacogenomic tests determine how genetic factors influence an individual’s response to drugs to ensure improved drug response and reduction of side effects. Inherited testing is concerned with identifying hereditary cancer syndromes that enhance cancer prevention and early detection efforts. Other specialized forms of genomic tests include screening tests for certain types of cancer or mutations that are more representative of the individual than the others. Both of these test types are revolutionizing cancer treatment, helping advance precision medicine, and improving the patient experience.
By Application, Targeted Therapy Selection segment expected to held the largest share
- Genomic cancer testing is divided into numerous and significant application categories that contribute to the development of the field of individualized treatment of oncological diseases. The selection of therapy to the target helps in achieving better results of therapy by first taking into consideration the genetic changes that occur in the cancer cells. Disease cyl also employs genomic tests to check for tumor evolution, recurrence or the manifestations of the tumor to treatment hence enabling real time management of the patients. Diagnostic testing involves analysing genetic data to determine the likelihood of cancer development, while prognostic testing focuses on assessing the probabilities of higher stage progression in order that treatment options may be designed properly. These tools are used to Savannah identify the individuals that will respond to the certain treatment for cancer. Screening includes conducting a Genetic Risk Profile to determine one’s susceptibility to specific types of cancer and therefore getting preventive or timely treatment. Finally, pharmacogenomic testing determines how a patients’ genetics impact their response to medications, which in turn guides the medications given and the dosage to be given to the patient in order to get the best out of every drug without having to go through the side effects. To the same overall intent, these various applications are supporting the expansion and utilization of genomic cancer tests in real practice.
Genomic Cancer Testing Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- This is because North America pretends to be the largest consumer in the genomic cancer testing market during the projected timeframe due to the following factors; a sound health care system, high uptake of novel technologies such as next-generation sequencing, and increased investment in genomics research. Having main market participants, such as diagnostics companies and pharmaceutical companies along with favorable reimbursment policies and raising awareness of personalized medicine contribute to the market growth in the area. Furthermore, the increase in the cancer-Causing disease and the significant interest in precision medicine motivate the genomic cancer testing market. Ongoing technological innovations coupled with a rising expenditure on healthcare sector will ensure North America dominates the genomic cancer testing market in the coming years.
Active Key Players in the Genomic Cancer Testing Market:
- Illumina, Inc. (USA),
- Thermo Fisher Scientific, Inc. (USA),
- Qiagen N.V. (Germany),
- F. Hoffmann-La Roche Ltd. (Switzerland),
- Foundation Medicine, Inc. (Roche) (USA),
- Invitae Corporation (USA),
- NeoGenomics Laboratories, Inc. (USA),
- Myriad Genetics, Inc. (USA),
- Genomic Health, Inc. (Exact Sciences Corporation) (USA),
- Caris Life Sciences (USA),
- ArcherDX, Inc. (Invitae Corporation) (USA),
- Guardant Health, Inc. (USA),
- Personal Genome Diagnostics Inc. (USA),
- Biocept, Inc. (USA)
- Tempus Labs, Inc. (USA)
- Other Active Players
|
Genomic Cancer Testing Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 16.67 Billion |
|
Forecast Period 2024-32 CAGR: |
17% |
Market Size in 2032: |
USD 48 Billion |
|
Segments Covered: |
By Test Type |
|
|
|
By Cancer Type |
|
||
|
By Technology |
|
||
|
By End-User |
|
||
|
By Biomarker Type |
|
||
|
By Service Provider |
|
||
|
By Application |
|
||
|
By Testing Setting |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Genomic Cancer Testing Market by By Test Type (2018-2032)
4.1 Genomic Cancer Testing Market Snapshot and Growth Engine
4.2 Market Overview
4.3 Genomic Profiling Tests
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
4.3.3 Key Market Trends, Growth Factors, and Opportunities
4.3.4 Geographic Segmentation Analysis
4.4 Liquid Biopsy Tests
4.5 Companion Diagnostic Tests
4.6 Pharmacogenomic Tests
4.7 Hereditary Cancer Tests
4.8 Other specialized genomic tests
Chapter 5: Genomic Cancer Testing Market by By Cancer Type (2018-2032)
5.1 Genomic Cancer Testing Market Snapshot and Growth Engine
5.2 Market Overview
5.3 Breast Cancer
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
5.3.3 Key Market Trends, Growth Factors, and Opportunities
5.3.4 Geographic Segmentation Analysis
5.4 Lung Cancer
5.5 Colorectal Cancer
5.6 Prostate Cancer
5.7 Ovarian Cancer
5.8 Melanoma
5.9 Leukemia
5.10 Lymphoma
5.11 Other specific cancer types
Chapter 6: Genomic Cancer Testing Market by By Technology (2018-2032)
6.1 Genomic Cancer Testing Market Snapshot and Growth Engine
6.2 Market Overview
6.3 NextGeneration Sequencing
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
6.3.3 Key Market Trends, Growth Factors, and Opportunities
6.3.4 Geographic Segmentation Analysis
6.4 Polymerase Chain Reaction
6.5 Fluorescence In Situ Hybridization
6.6 Microarray
6.7 Immunohistochemistry
6.8 Other genomic testing technologies
Chapter 7: Genomic Cancer Testing Market by By End-User (2018-2032)
7.1 Genomic Cancer Testing Market Snapshot and Growth Engine
7.2 Market Overview
7.3 Hospitals
7.3.1 Introduction and Market Overview
7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
7.3.3 Key Market Trends, Growth Factors, and Opportunities
7.3.4 Geographic Segmentation Analysis
7.4 Diagnostic Laboratories
7.5 Academic and Research Institutions
7.6 Cancer Centers
7.7 Other healthcare providers
Chapter 8: Genomic Cancer Testing Market by By Biomarker Type (2018-2032)
8.1 Genomic Cancer Testing Market Snapshot and Growth Engine
8.2 Market Overview
8.3 Genetic Biomarkers
8.3.1 Introduction and Market Overview
8.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
8.3.3 Key Market Trends, Growth Factors, and Opportunities
8.3.4 Geographic Segmentation Analysis
8.4 Protein Biomarkers
8.5 Molecular Biomarkers
8.6 Epigenetic Biomarkers
Chapter 9: Genomic Cancer Testing Market by By Service Provider (2018-2032)
9.1 Genomic Cancer Testing Market Snapshot and Growth Engine
9.2 Market Overview
9.3 Diagnostic Laboratories
9.3.1 Introduction and Market Overview
9.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
9.3.3 Key Market Trends, Growth Factors, and Opportunities
9.3.4 Geographic Segmentation Analysis
9.4 Biotechnology Companies
9.5 Pharmaceutical Companies
9.6 Contract Research Organizations
Chapter 10: Company Profiles and Competitive Analysis
10.1 Competitive Landscape
10.1.1 Competitive Benchmarking
10.1.2 Genomic Cancer Testing Market Share by Manufacturer (2024)
10.1.3 Industry BCG Matrix
10.1.4 Heat Map Analysis
10.1.5 Mergers and Acquisitions
10.2 ILLUMINA INC. (USA)
10.2.1 Company Overview
10.2.2 Key Executives
10.2.3 Company Snapshot
10.2.4 Role of the Company in the Market
10.2.5 Sustainability and Social Responsibility
10.2.6 Operating Business Segments
10.2.7 Product Portfolio
10.2.8 Business Performance
10.2.9 Key Strategic Moves and Recent Developments
10.2.10 SWOT Analysis
10.3 THERMO FISHER SCIENTIFIC INC. (USA)
10.4 QIAGEN N.V. (GERMANY)
10.5 F. HOFFMANN-LA ROCHE LTD. (SWITZERLAND)
10.6 FOUNDATION MEDICINE INC. (ROCHE) (USA)
10.7 INVITAE CORPORATION (USA)
10.8 NEOGENOMICS LABORATORIES INC. (USA)
10.9 MYRIAD GENETICS INC. (USA)
10.10 GENOMIC HEALTH INC. (EXACT SCIENCES CORPORATION) (USA)
10.11 CARIS LIFE SCIENCES (USA)
10.12 ARCHERDX INC. (INVITAE CORPORATION) (USA)
10.13 GUARDANT HEALTH INC. (USA)
10.14 PERSONAL GENOME DIAGNOSTICS INC. (USA)
10.15 BIOCEPT INC. (USA)
10.16 TEMPUS LABS INC. (USA)
10.17 OTHER ACTIVE PLAYERS
Chapter 11: Global Genomic Cancer Testing Market By Region
11.1 Overview
11.2. North America Genomic Cancer Testing Market
11.2.1 Key Market Trends, Growth Factors and Opportunities
11.2.2 Top Key Companies
11.2.3 Historic and Forecasted Market Size by Segments
11.2.4 Historic and Forecasted Market Size By By Test Type
11.2.4.1 Genomic Profiling Tests
11.2.4.2 Liquid Biopsy Tests
11.2.4.3 Companion Diagnostic Tests
11.2.4.4 Pharmacogenomic Tests
11.2.4.5 Hereditary Cancer Tests
11.2.4.6 Other specialized genomic tests
11.2.5 Historic and Forecasted Market Size By By Cancer Type
11.2.5.1 Breast Cancer
11.2.5.2 Lung Cancer
11.2.5.3 Colorectal Cancer
11.2.5.4 Prostate Cancer
11.2.5.5 Ovarian Cancer
11.2.5.6 Melanoma
11.2.5.7 Leukemia
11.2.5.8 Lymphoma
11.2.5.9 Other specific cancer types
11.2.6 Historic and Forecasted Market Size By By Technology
11.2.6.1 NextGeneration Sequencing
11.2.6.2 Polymerase Chain Reaction
11.2.6.3 Fluorescence In Situ Hybridization
11.2.6.4 Microarray
11.2.6.5 Immunohistochemistry
11.2.6.6 Other genomic testing technologies
11.2.7 Historic and Forecasted Market Size By By End-User
11.2.7.1 Hospitals
11.2.7.2 Diagnostic Laboratories
11.2.7.3 Academic and Research Institutions
11.2.7.4 Cancer Centers
11.2.7.5 Other healthcare providers
11.2.8 Historic and Forecasted Market Size By By Biomarker Type
11.2.8.1 Genetic Biomarkers
11.2.8.2 Protein Biomarkers
11.2.8.3 Molecular Biomarkers
11.2.8.4 Epigenetic Biomarkers
11.2.9 Historic and Forecasted Market Size By By Service Provider
11.2.9.1 Diagnostic Laboratories
11.2.9.2 Biotechnology Companies
11.2.9.3 Pharmaceutical Companies
11.2.9.4 Contract Research Organizations
11.2.10 Historic and Forecast Market Size by Country
11.2.10.1 US
11.2.10.2 Canada
11.2.10.3 Mexico
11.3. Eastern Europe Genomic Cancer Testing Market
11.3.1 Key Market Trends, Growth Factors and Opportunities
11.3.2 Top Key Companies
11.3.3 Historic and Forecasted Market Size by Segments
11.3.4 Historic and Forecasted Market Size By By Test Type
11.3.4.1 Genomic Profiling Tests
11.3.4.2 Liquid Biopsy Tests
11.3.4.3 Companion Diagnostic Tests
11.3.4.4 Pharmacogenomic Tests
11.3.4.5 Hereditary Cancer Tests
11.3.4.6 Other specialized genomic tests
11.3.5 Historic and Forecasted Market Size By By Cancer Type
11.3.5.1 Breast Cancer
11.3.5.2 Lung Cancer
11.3.5.3 Colorectal Cancer
11.3.5.4 Prostate Cancer
11.3.5.5 Ovarian Cancer
11.3.5.6 Melanoma
11.3.5.7 Leukemia
11.3.5.8 Lymphoma
11.3.5.9 Other specific cancer types
11.3.6 Historic and Forecasted Market Size By By Technology
11.3.6.1 NextGeneration Sequencing
11.3.6.2 Polymerase Chain Reaction
11.3.6.3 Fluorescence In Situ Hybridization
11.3.6.4 Microarray
11.3.6.5 Immunohistochemistry
11.3.6.6 Other genomic testing technologies
11.3.7 Historic and Forecasted Market Size By By End-User
11.3.7.1 Hospitals
11.3.7.2 Diagnostic Laboratories
11.3.7.3 Academic and Research Institutions
11.3.7.4 Cancer Centers
11.3.7.5 Other healthcare providers
11.3.8 Historic and Forecasted Market Size By By Biomarker Type
11.3.8.1 Genetic Biomarkers
11.3.8.2 Protein Biomarkers
11.3.8.3 Molecular Biomarkers
11.3.8.4 Epigenetic Biomarkers
11.3.9 Historic and Forecasted Market Size By By Service Provider
11.3.9.1 Diagnostic Laboratories
11.3.9.2 Biotechnology Companies
11.3.9.3 Pharmaceutical Companies
11.3.9.4 Contract Research Organizations
11.3.10 Historic and Forecast Market Size by Country
11.3.10.1 Russia
11.3.10.2 Bulgaria
11.3.10.3 The Czech Republic
11.3.10.4 Hungary
11.3.10.5 Poland
11.3.10.6 Romania
11.3.10.7 Rest of Eastern Europe
11.4. Western Europe Genomic Cancer Testing Market
11.4.1 Key Market Trends, Growth Factors and Opportunities
11.4.2 Top Key Companies
11.4.3 Historic and Forecasted Market Size by Segments
11.4.4 Historic and Forecasted Market Size By By Test Type
11.4.4.1 Genomic Profiling Tests
11.4.4.2 Liquid Biopsy Tests
11.4.4.3 Companion Diagnostic Tests
11.4.4.4 Pharmacogenomic Tests
11.4.4.5 Hereditary Cancer Tests
11.4.4.6 Other specialized genomic tests
11.4.5 Historic and Forecasted Market Size By By Cancer Type
11.4.5.1 Breast Cancer
11.4.5.2 Lung Cancer
11.4.5.3 Colorectal Cancer
11.4.5.4 Prostate Cancer
11.4.5.5 Ovarian Cancer
11.4.5.6 Melanoma
11.4.5.7 Leukemia
11.4.5.8 Lymphoma
11.4.5.9 Other specific cancer types
11.4.6 Historic and Forecasted Market Size By By Technology
11.4.6.1 NextGeneration Sequencing
11.4.6.2 Polymerase Chain Reaction
11.4.6.3 Fluorescence In Situ Hybridization
11.4.6.4 Microarray
11.4.6.5 Immunohistochemistry
11.4.6.6 Other genomic testing technologies
11.4.7 Historic and Forecasted Market Size By By End-User
11.4.7.1 Hospitals
11.4.7.2 Diagnostic Laboratories
11.4.7.3 Academic and Research Institutions
11.4.7.4 Cancer Centers
11.4.7.5 Other healthcare providers
11.4.8 Historic and Forecasted Market Size By By Biomarker Type
11.4.8.1 Genetic Biomarkers
11.4.8.2 Protein Biomarkers
11.4.8.3 Molecular Biomarkers
11.4.8.4 Epigenetic Biomarkers
11.4.9 Historic and Forecasted Market Size By By Service Provider
11.4.9.1 Diagnostic Laboratories
11.4.9.2 Biotechnology Companies
11.4.9.3 Pharmaceutical Companies
11.4.9.4 Contract Research Organizations
11.4.10 Historic and Forecast Market Size by Country
11.4.10.1 Germany
11.4.10.2 UK
11.4.10.3 France
11.4.10.4 The Netherlands
11.4.10.5 Italy
11.4.10.6 Spain
11.4.10.7 Rest of Western Europe
11.5. Asia Pacific Genomic Cancer Testing Market
11.5.1 Key Market Trends, Growth Factors and Opportunities
11.5.2 Top Key Companies
11.5.3 Historic and Forecasted Market Size by Segments
11.5.4 Historic and Forecasted Market Size By By Test Type
11.5.4.1 Genomic Profiling Tests
11.5.4.2 Liquid Biopsy Tests
11.5.4.3 Companion Diagnostic Tests
11.5.4.4 Pharmacogenomic Tests
11.5.4.5 Hereditary Cancer Tests
11.5.4.6 Other specialized genomic tests
11.5.5 Historic and Forecasted Market Size By By Cancer Type
11.5.5.1 Breast Cancer
11.5.5.2 Lung Cancer
11.5.5.3 Colorectal Cancer
11.5.5.4 Prostate Cancer
11.5.5.5 Ovarian Cancer
11.5.5.6 Melanoma
11.5.5.7 Leukemia
11.5.5.8 Lymphoma
11.5.5.9 Other specific cancer types
11.5.6 Historic and Forecasted Market Size By By Technology
11.5.6.1 NextGeneration Sequencing
11.5.6.2 Polymerase Chain Reaction
11.5.6.3 Fluorescence In Situ Hybridization
11.5.6.4 Microarray
11.5.6.5 Immunohistochemistry
11.5.6.6 Other genomic testing technologies
11.5.7 Historic and Forecasted Market Size By By End-User
11.5.7.1 Hospitals
11.5.7.2 Diagnostic Laboratories
11.5.7.3 Academic and Research Institutions
11.5.7.4 Cancer Centers
11.5.7.5 Other healthcare providers
11.5.8 Historic and Forecasted Market Size By By Biomarker Type
11.5.8.1 Genetic Biomarkers
11.5.8.2 Protein Biomarkers
11.5.8.3 Molecular Biomarkers
11.5.8.4 Epigenetic Biomarkers
11.5.9 Historic and Forecasted Market Size By By Service Provider
11.5.9.1 Diagnostic Laboratories
11.5.9.2 Biotechnology Companies
11.5.9.3 Pharmaceutical Companies
11.5.9.4 Contract Research Organizations
11.5.10 Historic and Forecast Market Size by Country
11.5.10.1 China
11.5.10.2 India
11.5.10.3 Japan
11.5.10.4 South Korea
11.5.10.5 Malaysia
11.5.10.6 Thailand
11.5.10.7 Vietnam
11.5.10.8 The Philippines
11.5.10.9 Australia
11.5.10.10 New Zealand
11.5.10.11 Rest of APAC
11.6. Middle East & Africa Genomic Cancer Testing Market
11.6.1 Key Market Trends, Growth Factors and Opportunities
11.6.2 Top Key Companies
11.6.3 Historic and Forecasted Market Size by Segments
11.6.4 Historic and Forecasted Market Size By By Test Type
11.6.4.1 Genomic Profiling Tests
11.6.4.2 Liquid Biopsy Tests
11.6.4.3 Companion Diagnostic Tests
11.6.4.4 Pharmacogenomic Tests
11.6.4.5 Hereditary Cancer Tests
11.6.4.6 Other specialized genomic tests
11.6.5 Historic and Forecasted Market Size By By Cancer Type
11.6.5.1 Breast Cancer
11.6.5.2 Lung Cancer
11.6.5.3 Colorectal Cancer
11.6.5.4 Prostate Cancer
11.6.5.5 Ovarian Cancer
11.6.5.6 Melanoma
11.6.5.7 Leukemia
11.6.5.8 Lymphoma
11.6.5.9 Other specific cancer types
11.6.6 Historic and Forecasted Market Size By By Technology
11.6.6.1 NextGeneration Sequencing
11.6.6.2 Polymerase Chain Reaction
11.6.6.3 Fluorescence In Situ Hybridization
11.6.6.4 Microarray
11.6.6.5 Immunohistochemistry
11.6.6.6 Other genomic testing technologies
11.6.7 Historic and Forecasted Market Size By By End-User
11.6.7.1 Hospitals
11.6.7.2 Diagnostic Laboratories
11.6.7.3 Academic and Research Institutions
11.6.7.4 Cancer Centers
11.6.7.5 Other healthcare providers
11.6.8 Historic and Forecasted Market Size By By Biomarker Type
11.6.8.1 Genetic Biomarkers
11.6.8.2 Protein Biomarkers
11.6.8.3 Molecular Biomarkers
11.6.8.4 Epigenetic Biomarkers
11.6.9 Historic and Forecasted Market Size By By Service Provider
11.6.9.1 Diagnostic Laboratories
11.6.9.2 Biotechnology Companies
11.6.9.3 Pharmaceutical Companies
11.6.9.4 Contract Research Organizations
11.6.10 Historic and Forecast Market Size by Country
11.6.10.1 Turkiye
11.6.10.2 Bahrain
11.6.10.3 Kuwait
11.6.10.4 Saudi Arabia
11.6.10.5 Qatar
11.6.10.6 UAE
11.6.10.7 Israel
11.6.10.8 South Africa
11.7. South America Genomic Cancer Testing Market
11.7.1 Key Market Trends, Growth Factors and Opportunities
11.7.2 Top Key Companies
11.7.3 Historic and Forecasted Market Size by Segments
11.7.4 Historic and Forecasted Market Size By By Test Type
11.7.4.1 Genomic Profiling Tests
11.7.4.2 Liquid Biopsy Tests
11.7.4.3 Companion Diagnostic Tests
11.7.4.4 Pharmacogenomic Tests
11.7.4.5 Hereditary Cancer Tests
11.7.4.6 Other specialized genomic tests
11.7.5 Historic and Forecasted Market Size By By Cancer Type
11.7.5.1 Breast Cancer
11.7.5.2 Lung Cancer
11.7.5.3 Colorectal Cancer
11.7.5.4 Prostate Cancer
11.7.5.5 Ovarian Cancer
11.7.5.6 Melanoma
11.7.5.7 Leukemia
11.7.5.8 Lymphoma
11.7.5.9 Other specific cancer types
11.7.6 Historic and Forecasted Market Size By By Technology
11.7.6.1 NextGeneration Sequencing
11.7.6.2 Polymerase Chain Reaction
11.7.6.3 Fluorescence In Situ Hybridization
11.7.6.4 Microarray
11.7.6.5 Immunohistochemistry
11.7.6.6 Other genomic testing technologies
11.7.7 Historic and Forecasted Market Size By By End-User
11.7.7.1 Hospitals
11.7.7.2 Diagnostic Laboratories
11.7.7.3 Academic and Research Institutions
11.7.7.4 Cancer Centers
11.7.7.5 Other healthcare providers
11.7.8 Historic and Forecasted Market Size By By Biomarker Type
11.7.8.1 Genetic Biomarkers
11.7.8.2 Protein Biomarkers
11.7.8.3 Molecular Biomarkers
11.7.8.4 Epigenetic Biomarkers
11.7.9 Historic and Forecasted Market Size By By Service Provider
11.7.9.1 Diagnostic Laboratories
11.7.9.2 Biotechnology Companies
11.7.9.3 Pharmaceutical Companies
11.7.9.4 Contract Research Organizations
11.7.10 Historic and Forecast Market Size by Country
11.7.10.1 Brazil
11.7.10.2 Argentina
11.7.10.3 Rest of SA
Chapter 12 Analyst Viewpoint and Conclusion
12.1 Recommendations and Concluding Analysis
12.2 Potential Market Strategies
Chapter 13 Research Methodology
13.1 Research Process
13.2 Primary Research
13.3 Secondary Research
|
Genomic Cancer Testing Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 16.67 Billion |
|
Forecast Period 2024-32 CAGR: |
17% |
Market Size in 2032: |
USD 48 Billion |
|
Segments Covered: |
By Test Type |
|
|
|
By Cancer Type |
|
||
|
By Technology |
|
||
|
By End-User |
|
||
|
By Biomarker Type |
|
||
|
By Service Provider |
|
||
|
By Application |
|
||
|
By Testing Setting |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Frequently Asked Questions :
The forecast period in the Genomic Cancer Testing Market research report is 2024-2032.
Illumina, Inc. (USA), Thermo Fisher Scientific, Inc. (USA), Qiagen N.V. (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Foundation Medicine, Inc. (Roche) (USA), Invitae Corporation (USA), NeoGenomics Laboratories, Inc. (USA), Myriad Genetics, Inc. (USA), Genomic Health, Inc. (Exact Sciences Corporation) (USA), Caris Life Sciences (USA), ArcherDX, Inc. (Invitae Corporation) (USA), Guardant Health, Inc. (USA), Personal Genome Diagnostics Inc. (USA), Biocept, Inc. (USA), Tempus Labs, Inc. (USA), and Other Active Players.
The Genomic Cancer Testing Market is segmented into By Test Type, By Cancer Type, By Technology, By End-User , By Biomarker Type, By Service Provider, By Application, By Testing Setting and region. By Test Type (Genomic Profiling Tests, Liquid Biopsy Tests, Companion Diagnostic Tests, Pharmacogenomic Tests, Hereditary Cancer Tests, Other specialized genomic tests), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Melanoma, Leukemia, Lymphoma, Other specific cancer types), By Technology (NextGeneration Sequencing, Polymerase Chain Reaction, Fluorescence In Situ Hybridization, Microarray, Immunohistochemistry, Other genomic testing technologies), By End-User (Hospitals, Diagnostic Laboratories, Academic and Research Institutions, Cancer Centers, Other healthcare providers), By Biomarker Type (Genetic Biomarkers, Protein Biomarkers, Molecular Biomarkers, Epigenetic Biomarkers), By Service Provider (Diagnostic Laboratories, Biotechnology Companies, Pharmaceutical Companies, Contract Research Organizations), By Application (Targeted Therapy Selection, Disease Monitoring, Prognostic Testing, Companion Diagnostics, Risk Assessment, Pharmacogenomic Testing), By Testing Setting (In-House Testing, Outsourced Testing). By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, The Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New-Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).
Genomic cancer testing refers to the process of analyzing the genetic makeup of cancer cells to identify specific mutations, alterations, or variations in DNA that may influence the development, progression, and treatment of cancer. This testing is crucial for understanding the molecular characteristics of a patient's cancer, which can help guide personalized treatment decisions. By using techniques such as next-generation sequencing (NGS), genomic cancer testing enables the identification of targeted therapies that are most likely to be effective based on the genetic profile of the tumor. It plays a vital role in early cancer detection, monitoring treatment response, and predicting disease recurrence, offering a more tailored approach to oncology care.
Genomic Cancer Testing Market Size Was Valued at USD 16.67 Billion in 2023, and is Projected to Reach USD 48 Billion by 2032, Growing at a CAGR of 17% From 2024-2032.
